This press release contains forward-looking statements about Forteo for the treatment of osteoporosis. It reflects Lilly's current beliefs; however, as with any such undertaking, there are substantial risks and uncertainties in the process of drug development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date or that Forteo will continue to be commercially successful. For further discussion of these and other risks and uncertainties, please see Lilly's latest Forms 10-Q and 10-K filed with the . Securities and Exchange Commission . Lilly undertakes no duty to update forward-looking statements.
"The first dose gave me muscle pain and weakness that left me in bed trying not to move in an attempt to minimize the pain. For two days every breath I took was accompanied by significant pain. Because even though I was laying as still as possible, I still needed to breathe I was assured that the pain is milder the second time around. They were right, the pain did not outweigh my will to move. Which was fortunate because I had nausea and vomiting the next day. My doctor was able to prescribe anti nausea meds, which helped significantly. I suggest anyone who takes this have someone who can help them out the next few days. Just in case."
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about FORTEO as a potential treatment for patients with severe osteoporosis, and reflects Lilly 's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date or that FORTEO will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly 's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission . Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.